|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jaiswal M, LaRusso NF, Burgart LJ and
Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA
repair in cholangiocarcinoma cells by a nitric oxide-dependent
mechanism. Cancer Res. 60:184–190. 2000.PubMed/NCBI
|
|
6
|
McMilan DC: The systemic
inflammation-based Glasgow prognostic score: A decade of experience
in patients with cancer. Cancer Treat Rev. 39:534–540. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Smith RA, Bosonnet L, Raraty M, Sutton R,
Neoptolemos JP, Campbell F and Ghaneh P: Preoperative
platelet-lymphocyte ratio is an independent significant prognostic
marker in resected pancreatic ductal adenocarcinoma. Am J Surg.
197:466–472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tomita M, Shimizu T, Ayabe T, Yonei A and
Onitsuka T: Preoperative neutrophil to lymphocyte ratio as a
prognostic predictor after curative resection of non-small lung
cancer. Anticancer Res. 31:2995–2998. 2011.PubMed/NCBI
|
|
9
|
Pinato DJ, Shiner RJ, Seckl MJ, Stebbing
J, Sharma R and Mauri FA: Prognostic performance of
inflammation-based prognostic indices in primary operable non-small
cell lung cancer. Br J Cancer. 110:1930–1935. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Zhang L, Zhu K, Shi B, Yin Y, Zhu
J, Yue D, Zhang B and Wang C: Prognostic significance of
combination of preoperative platelet count and
neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small
cell lung cancer: Based on a large cohort study. PLoS One.
10:e01264962015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shibutani M, Maeda K, Nagahara H, Ohtani
H, Iseki Y, Ikeya T, Sugano K and Hirakawa K: The prognostic
significance of a postoperative systemic inflammatory response in
patients with colorectal cancer. World J Surg Oncol. 13:1942015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Albayrak S, Zengin K, Tanik S, Atar M,
Unal SH, Imamoglu MA and Gurdal M: Can the neutrophil-to-lymphocyte
ratio be used to predict recurrence and progression of
non-muscle-invasive bladder cancer? Kaohsiung J Med Sci.
32:327–333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong YW, Shi YQ, He LW and Su PZ:
Prognostic significance of neutrophil-to-lymphocyte ratio in rectal
cancer: A meta-analysis. Onco Targets Ther. 9:3127–3134.
2016.PubMed/NCBI
|
|
14
|
Nakamura K, Nagasaka T, Nishida T, Haruma
T, Ogawa C, Kusumoto T, Seki N and Hiramatsu Y: Neutrophil to
lymphocyte ratio in the pre-treatment phase of final-line
chemotherapy predicts the outcome of patients with recurrent
ovarian cancer. Oncol Lett. 11:3975–3981. 2016.PubMed/NCBI
|
|
15
|
Aino H, Sumie S, Niizeki T, Kuromatsu R,
Tajiri N, Nakano M, Satani M, Okamura S, Shimose S, Miyahara K and
Torimura T: The systemic inflammatory response as a prognostic
factor for advanced hepatocellular carcinoma with extrahepatic
metastasis. Mol Clin Oncol. 5:83–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ding PR, An X, Zhang RX, Fang YJ, Li LR,
Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, et al: Elevated preoperative
neutrophil to lymphocyte ratio predicts risk of recurrence
following curative resection of stage IIA colon cancer. Int J
Colorectal Dis. 25:1427–1433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jung MR, Park YK, Jeong O, Seon JW, Ryu
SY, Kim DY and Kim YJ: Elevated preoperative neutrophil to
lymphocyte ratio predicts poor survival following resection in late
stage gastric cancer. J Surg Oncol. 104:504–510. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stotz M, Gerger A, Eisner F, Szkandera J,
Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner
C, et al: Increased neutrophil-lymphocyte ratio is a poor
prognostic factor in patients with primary operable and inoperable
pancreatic cancer. Br J Cancer. 109:416–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McMillan DC: Systemic inflammation,
nutritional status and survival in patients with cancer. Curr Opin
Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zahorec R: Ratio of neutrophil to
lymphocyte count-rapid and simple parameter of systemic
inflammation and stress in critically ill. Bratisl Lek Listy.
102:5–14. 2001.(In English, Slovak). PubMed/NCBI
|
|
22
|
Shirasaka T, Shimamoto Y, Ohshimo H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sugimachi K, Maehara Y, Horikoshi N,
Shimada Y, Sakata Y, Mitachi Y and Taguchi T: An early phase II
study of oral S-1, a newly developed 5-fluorouracil derivative foe
advanced and recurrent gastrointestinal cancers. S-1
Gastrointestinal Cancer Study Group. Oncology. 57:202–210. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi
K, Mitachi Y and Taguchi T: Late phase II study of novel oral
fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1
M otastat potassium) in advanced gastric cancer patients. Eur J
Cancer. 34:1715–1720. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koizumi W, Kurihara M, Nakano S and
Hasegawa K: Phase II study of S-1, a novel oral derivative of
5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative
Gastric Cancer Study Group. Oncology. 58:191–197. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Japanese Gastric Cancer Association:
Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric
Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shibata M and Gonda K: Cachexia,
immunological participationIn: Horizons in Cancer Research. 58.
Nova Science Publishers Inc; New York: 2015
|
|
28
|
Tisdale MJ: Biology of cachexia. J Natl
Cancer Inst. 89:1763–1773. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shibata M, Nezu T, Kanou H, Abe H,
Takekawa M and Fukuzawa M: Decreased production of interleukin-12
and type 2 immune responses are marked in cachectic patients with
colorectal and gastric cancer. J Clin Gastroenterol. 34:416–420.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shibata M, Nagata Y, Kimura T, Kanou H,
Nezu T, Takekawa M and Fukuzawa M: Elevated serum concentration of
interleukin-1 receptor antagonist (IL-1ra) is correlated to
interleukin-6 and to hypoalbuminemia in cachectic patients with
colorectal cancer. Int J Clin Oncol. 5:116–120. 2000. View Article : Google Scholar
|
|
31
|
Shibata M and Takekawa M: Increased serum
concentration of circulating soluble receptor for interleukin-2 and
its effect as a prognostic indicator in cachectic patients with
gastric and colorectal cancer. Oncology. 56:54–58. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ohki S, Shibata M, Gonda K, Machida T,
Shimura T, Nakamura I, Ohtake T, Koyama Y, Suzuki S, Ohto H and
Takenoshita S: Circulating myeloid-derived suppressor cells are
increased and correlated to immune suppression, inflammation and
hypoproteinemia in patients with cancer. Oncol Rep. 28:453–458.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakamura I, Shibata M, Gonda K, Yazawa T,
Shimura T, Anazaa T, Suzuki S, Sakurai K, Koyama Y, Ohto H, et al:
Serum levels of vascular endothelial growth factor are increased
and correlated with malnutrition, immunosuppression involving MDSCs
and systemic inflammation in patient with cancer of the digestive
system. Oncol Lett. 5:1682–1686. 2013.PubMed/NCBI
|
|
34
|
Suzuki Y, Mimura K, Yoshimoto Y, Watanabe
M, Ohkubo Y, Izawa S, Murata K, Fujii H, Nakano T and Kono K:
Immunogenic tumor cell death induced by chemoradiotherapy in
patients with esophageal squamous cell carcinoma. Cancer Res.
72:3967–3976. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yoshimoto Y, Kono K and Suzuki Y:
Anti-tumor immune responses induced by radiotherapy: A review.
Fukushima J Med Sci. 61:13–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garg AD, Galluzzi L, Apetoh L, Baert T,
Birge RB, Pedro Bravo-San JM, Breckpot K, Brough D, Chaurio R,
Cirone M, et al: Molecular and translational classifications of
DAMPs in immunogenic cell death. Front Immunol. 6:5882015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang RF and Wang HY: Immune targets and
neoantigens for cancer immunotherapy and precision medicine. Cell
Res. 27:11–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
